Ignyta

Ignyta was a biotechnology company based in San Diego, California, dedicated to developing personalized medicine and targeted therapies, primarily for oncology and other serious diseases. The company specialized in precision medicine approaches, aiming to create highly specific treatments tailored to individual patient profiles and the unique genetic characteristics of their conditions. Through its focused development efforts, Ignyta's portfolio collectively delivered seven approved therapeutic products across oncology, immunology, and drug delivery indications, demonstrating its impact in critical therapeutic areas. Jonathan Lim, who served as Co-Founder and Chairman, played a pivotal role in steering the company's strategic direction and its commitment to innovative therapeutic solutions. Ignyta's significant contributions to the precision medicine sector culminated in its acquisition as of February 18, 2025, integrating its specialized capabilities into a larger pharmaceutical framework. The company was founded in 2011 by Jonathan Lim.